Tag: Phase II Trial

Peanuts

Study: Few People with Peanut Allergy Tolerate Peanut after Stopping OIT

Continuing with a modest dose confers more protection, NIH-funded study finds.
Patient Undergoing SLIT

New Peanut Allergy Treatment Passes Phase 2 Trial, Shows Effectiveness and...

UNC School of Medicine researchers show that tiny under-the-tongue doses of peanut protein can offer safe and substantial protection against peanut allergy.
Eggs

Aimmune Enrolls First Patient in Phase 2 Trial of AR201 for...

AR201 is the second development program that Aimmune is advancing to phase 2 using its Characterized Oral Desensitization ImmunoTherapy (CODIT™) platform.
Eggs

Aimmune to Begin Phase 2 Trials of Egg Allergy OIT Candidate

AR201 for Egg Allergy Phase 2 Initiation Planned for 2019.
AR101+dupilumab

Aimmune Therapeutics Announces Initiation of Phase 2 Study of AR101 With...

Trial Will Build on the Positive, Pivotal Phase 3 PALISADE Trial of AR101.
AR101+dupilumab

Phase II Trials of AR101 with Dupilumab for Peanut Allergy to...

Study scheduled to commence next week.
Lactobacillus rhamnosus

Enrollment Complete for Phase 2b Probiotic Oral Immunotherapy Treatment Candidate

Study to provide evidence of longer lasting tolerance to peanut in a larger number of patients.
Jigsaw Puzzle

Milk and Peanut Clinical Trial Advances

Announcements regarding two food allergy therapies that are in or advancing toward clinical trials were made yesterday.
Xolair (omalizumab)

Study: Drug Increases Speed and Safety of OIT for Multiple Allergies

Combining omalizumab with OIT is safe and effective for treating multiple food allergies simultaneously.
Peanut Therapy

Aimmune, Regeneron and Sanofi Collaborate on Combination Peanut Therapy

More exciting news as pharma companies work to extend the effectiveness of their therapies in combination.